key: cord-0790388-27x3vio1
authors: Gieger, Tracy L.; Hosgood, Giselle; Taboada, Joseph; Wolfsheimer, Karen J.; Mueller, Peter B.
title: Thyroid Function and Serum Hepatic Enzyme Activity in Dogs after Phenobarbital Administration
date: 2008-06-28
journal: J Vet Intern Med
DOI: 10.1111/j.1939-1676.2000.tb01167.x
sha: d8b182c5528c93100f975d2d01bec9b1824e5d75
doc_id: 790388
cord_uid: 27x3vio1

Phenobarbital is the drug of choice for control of canine epilepsy. Phenobarbital induces hepatic enzyme activity, can be hepatotoxic, and decreases serum thyroxine (T(4)) concentrations in some dogs. The duration of liver enzyme induction and T(4) concentration decreases after discontinuation of phenobarbital is unknown. The purpose of this study was to characterize the changes in serum total T(4) (TT(4)), free T(4) (FT(4)), thyroid‐stimulating hormone (TSH), cholesterol and albumin concentrations, and activities in serum of alanine aminotransferase (ALT), alkaline phosphatase (ALP), and gamma‐glutamyl transferase (GGT) after discontinuation of long‐term phenobarbital administration in normal dogs. Twelve normal dogs were administered phenobarbital at a dosage of approximately 4.4–6.6 mg/kg PO ql2h for 27 weeks. Blood was collected for analysis before and after 27 weeks of phenobarbital administration and then weekly for 10 weeks after discontinuation of the drug. The dogs were clinically normal throughout the study period. Serum ALT and ALP activity and TSH and cholesterol concentrations were significantly higher than baseline at week 27. Serum T(4) and FT(4) were significantly lower. Serum albumin and GGT were not changed from baseline at week 27. Changes in estimate of thyroid function (TT(4), FT(4), TSH) persisted for 1–4 weeks after discontinuation of phenobarbital, whereas changes in hepatic enzyme activity (ALT, ALP) and cholesterol concentration resolved in 3–5 weeks. To avoid false positive results, it is recommended that thyroid testing be performed at least 4 weeks after discontinuation of phenobarbital administration. Elevated serum activity of hepatic enzymes 6–8 weeks after discontinuation of phenobarbital may indicate hepatic disease.

E pilepsy, including both inherited (idiopathic) and acquired forms, is a common neurologic disease of dogs. 1 Phenobarbital, a barbiturate, is currently the drug of choice for control of canine epilepsy and other seizure disorders because of its low cost, efficacy, and minimal toxicity. [1] [2] [3] Phenobarbital is an effective anticonvulsant in 60-80% of dogs if a serum concentration of 15-40 g/mL is maintained. 4 Potential adverse effects of phenobarbital administration include sedation, polyphagia, polyuria and polydipsia, and teratogenicity. 1, 4 One report of 3 dogs documented neutropenia and thrombocytopenia with long-term administration of phenobarbital. 5 In addition, phenobarbital is hepatotoxic in some dogs. [6] [7] [8] Phenobarbital is a potent inducer of cytochrome p450 and hepatic microsomal enzymes in dogs, with subsequent increases in serum activity of these enzymes making it difficult to detect hepatotoxicosis. 1, 3, 4 When enzyme induction resolves after withdrawal of phenobarbital is unknown, which confounds such determinations further.

In dogs, phenobarbital decreases total thyroxine (TT 4 ) and free T 4 (FT 4 ) concentrations and administration results in an increase in thyroid-stimulationg hormone (TSH) con-centration. [9] [10] [11] [12] Although the mechanism of these changes remains unproven in dogs, serum T 4 concentration is suspected to be decreased because of increased metabolism and excretion of the hormone secondary to hepatic microsomal enzyme induction, as is the case in humans and rodents. 11, 13, 14 The length of time necessary for thyroid hormone concentrations to return to normal after discontinuation of long-term phenobarbital administration in the dog is unknown.

The purpose of this study was to characterize the changes in TT 4 , FT 4 , TSH and cholesterol concentrations, liver-related enzyme activities (alanine aminotransferase [ALT], alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT]), and albumin after discontinuation of long-term phenobarbital administration (27 weeks) in normal dogs. This study represented a 2nd phase of a larger study examining the effects of long-term phenobarbital administration on liver, thyroid, and adrenal function testing. 12

Twelve adult neutered male dogs of various breeds, ranging from 11 to 23 kg in initial body weight and from 1 to 6 years in age, were housed in concrete outdoor kennels and were exercised once daily in a common grass lot. Breeds included 4 hounds, 2 medium-sized mixed breed dogs, and 6 Beagles. They received water and a commercial dry dog food a ad libitum and were cared for according to the Guide for the Care and Use of Laboratory Animals of the National Research Council. 15 Drugs or vaccines administered or chemicals used on every dog included yearly vaccinations against canine distemper, parvovirus, adenovirus 2, leptospirosis, coronavirus, parainfluenza virus, and rabies, with the last vaccination administered at least 5 months before the start of the study; monthly heartworm preventative b ; and daily disinfection of the concrete runs with a quaternary ammonia salt solution. c All dogs were examined before phenobarbital initiation to determine general health status and to obtain basal values for the variables measured during the study. Each dog was used as its own control. Pretreatment evaluation had included physical examination, a full chemistry panel 4 weeks before and immediately before phenobarbital initiation, complete blood count, and urinalysis. A Knott's concentration test for microfilaria and an enzyme-linked immunosorbent assay for antigen of adult heartworms were performed to rule out dirofilariosis. Feed was withdrawn at 5 PM on the days before all blood collections, providing a fasting time of at least 15 hours.

After collection of pretreatment values, a 27-week treatment course of phenobarbital d was initiated at a dosage of 4.4-6.6 mg/kg PO q12h. Selected serum liver and thyroid variables were obtained after 5, 9, 17, 21 , and 27 weeks of treatment. Phenobarbital was discontinued in all 12 dogs immediately before the beginning of this study. 12 Serum was collected at week 27 and at weekly intervals thereafter for 10 weeks; thus, data for week 27 represented baseline for this study. Evaluation of liver enzyme activity in serum (ALP, ALT, GGT) and albumin, TT 4 , FT 4 , TSH, and cholesterol concentrations were performed at weeks 1-3, 5, 7, and 9 (ALP, ALT, GGT, albumin, and cholesterol); weeks 1-10 (TT 4 ); weeks 1, 2, 4-6, 8, and 10 (FT 4 ); and weeks 1, 2, 4-8, and 10 (TSH). Evaluation during and after phenobarbital administration included daily observations of activity and behavior and biweekly measurement of body weight and physical examination.

Serum chemistry panels, e complete blood counts, f urinalyses, g and Knott's and occult heartworm h tests were performed with standard laboratory equipment and assay techniques validated for the respective laboratories.

Total T 4 concentrations were measured using a commercially available radioimmunoassay (RIA). i Biological specificity was demonstrated by revealing that injected TSH resulted in an increase in serum TT 4 concentrations (Ͼ48 nmol/L) after 6 hours in 12 healthy dogs. Lowend sensitivity for the assay, defined as the apparent concentration 2 standard deviations (SD) below the counts at maximum binding, was 3.2 nmol/L. The intraassay coefficient of variation for 30 replicates with a mean concentration of 32.5 nmol/L was 4.9%. The interassay coefficient of variation for a single sample performed in duplicate in 15 assays, with a mean concentration of 30.8 nmol/L, was 7.1%. A normal reference range of 52 healthy dogs (32 pets belonging to Louisiana State University [LSU] students, faculty, or staff plus 20 research dogs of various breeds) of both sexes ranging in age from 1 to 12 years of age was 24.1 Ϯ 15.8 nmol/L (mean Ϯ 2 SD).

FT 4 concentrations were measured using a commercially available RIA. j Biological specificity was demonstrated by revealing that injected TSH resulted in an increase in serum FT 4 concentrations (Ͼ34.5) pmol/L after 6 hours in 12 healthy dogs. Low-end sensitivity for the assay, as previously defined, was 1.9 pmol/L. The intraassay coefficient of variation for 20 replicates with a mean concentration of 13.6 pmol/L was 12.4%. The interassay coefficient of variation for a single sample in duplicate in 9 assays, with a mean concentration of 31.8 pmol/L, was 12.8%. A normal reference range of 72 healthy dogs (52 pets belonging to LSU students, faculty, or staff plus 20 research dogs of various breeds) of both sexes, ranging in age from 1 to 12 years of age was 17.3 Ϯ 12.2 pmol/L (mean Ϯ 2 SD).

TSH concentrations were measured using a commercially available immunoradiometric assay. k Biological specificity was indicated by the company by revealing an increase in TSH concentrations (Ͼ1.0 ng/ mL) after surgical removal of the thyroid glands in 6 healthy dogs. In addition, elevated TSH concentrations (Ͼ0.8 ng/mL) were demonstrated in our laboratory in 10 dogs with clinical signs of hypothyroidism, very low concentrations of TT 4 (Ͻ3.2 nmol/L) and FT 4 (Ͻ1.9 nmol/ L), and clinical response to thyroxine supplementation. Low-end sensitivity for the assay, as previously defined, was 0.1 ng/mL. The intraassay coefficient of variation for 24 replicates with a mean concentration of 0.31 ng/mL was 6.0%. The interassay coefficient of variation for a single sample performed in duplicate in 14 assays, with a mean concentration of 0.30 ng/mL, was 7.9%. A normal reference range of 44 healthy dogs (pets of various breeds, belonging to LSU students, faculty, or staff) of both sexes and ranging in age from 1 to 12 years of age was 0.18 Ϯ 0.175 (mean Ϯ 2 SD).

All data were considered continuous and evaluated for normality using the Shapiro-Wilk statistic. The data were considered to follow a normal distribution with failure to reject the null hypothesis of normality at P Յ .05. All data were analyzed using the model

where the effect of dog was considered random (therefore the interaction between dog and week was also random). A two-sided hypothesis with ␣ ϭ 0.05 was used to determine the significance of week. Where week had a significant effect, comparisons of data from each week after discontinuation of phenobarbital were made to data from week 27 (baseline) using adjusted least-squares means with a Dunnet's test maintaining an experiment-wise error of ␣ ϭ 0.05. Thus, where a significant difference in the data from week 27 was noted, unless specified, the P value was Ͻ.05. Proc mixed l was used for the analysis. The data are summarized and graphed as mean Ϯ SEM. 16

Serum ALT, ALP, and cholesterol concentrations were significantly higher at week 27, whereas GGT and albumin remained unchanged from values before administration of phenobarbital. Serum ALP activity was significantly decreased from week 27 at weeks 1-9 after discontinuation of phenobarbital (Fig 1) . Serum ALT activity was not significantly different from week 27 at weeks 1-3 after discontinuation of phenobarbital but was significantly decreased from week 27 at weeks 5-9 (Fig 1) . Serum GGT activity was significantly increased above week 27 at weeks 1-7 after discontinuation of phenobarbital but was not significantly different from week 27 at week 9 (Fig 1) . Serum albumin concentration was not significantly different from week 27 at weeks 1 and 3 after discontinuation of phenobarbital but was significantly increased from week 27 at weeks 2, 5, 7, and 9 (Fig 2) . Serum cholesterol was significantly decreased from week 27 at weeks 2, 3, 5, 7, and 9 after discontinuation of phenobarbital (Fig 2) . TT 4 and FT 4 were significantly decreased, whereas TSH concentration was significantly increased at week 27 from values before phenobarbital administration. Serum TT 4 concentration was not significantly different from week 27 at week 3 after discontinuation of phenobarbital but was significantly increased from week 27 at weeks 1, 2, and 4-10 (Fig 3) . Serum FT 4 concentration was not significantly different from week 27 at weeks 1, 2, 4, and 10 after discontinuation of phenobarbital but was significantly increased from week 27 at weeks 5, 6, and 8 (Fig 3) . Serum TSH concentration was not significantly different from week 27 at anytime after discontinuation of phenobarbital (Fig 3) .

In dogs with epilepsy or other seizure disorders, lifelong treatment with phenobarbital is often required. However, occasions occur where the drug may be withdrawn. Potential reasons include lack of seizure activity for an extended period, the desire to switch to a potentially less toxic anticonvulsant such as potassium bromide, or toxicity related to phenobarbital administration. 1 Hepatotoxicosis is a limiting factor to the use of phenobarbital as an anticonvulsant in some dogs. 1, 3, 6, 7, [17] [18] [19] However, determining if increases in serum activity of liver specific enzymes in a dog presenting for nonspecific clinical signs are due to hepatotoxicosis or because of a drug-induced enzyme induction can be difficult. When hepatotoxicosis is suspected, it is recommended that phenobarbital be discontinued and that the anticonvulsant treatment regimen be changed if possible.

Although serum ALP and ALT are increased by phenobarbital administration, AST and total bilirubin and bile acid concentrations are not and therefore are potential indicators of hepatotoxicosis. 3, 8, 12 In a retrospective study of 18 dogs with hepatotoxicosis secondary to phenobarbital administration, hypoalbuminemia occurred in 75%, and elevations in ALP, ALT, bile acids, and total bilirubin were documented in 100, 85, 33, and 40%, respectively. 18 The average duration of treatment was 39 months, and 75% of dogs had a serum phenobarbital concentration of greater than 40 g/mL. Examination of liver biopsies of 3 dogs revealed hepatic fibrosis and nodular regeneration. Reduction of the phenobarbital dose or discontinuation of the drug resulted in clinical improvement in 60% of dogs. Serum phenobarbital concentrations did not decrease for several days, but the changes in hepatic enzyme activity in serum after phenobarbital reduction or discontinuation were not reported. 18 The present study has clinical relevance in that activity of hepatic enzymes in serum that is still significantly abnormal at least 6 weeks after discontinuation of phenobarbital should lead the clinician to reevaluate the dog for hepatotoxicosis or other liver disease. In the dogs of this study, changes in serum activity of hepatic enzymes (ALT, ALP, GGT) and cholesterol concentration resolved 1-5 weeks after discontinuation of the drug. Based on these findings, it can be recommended that serum ALP, ALT, GGT, and cholesterol be reevaluated at least 6 weeks after discontinuing drug therapy.

In dogs, ALP can be elevated secondary to cholestasis, osteolysis, endogenous or exogenous corticosteroids, or drug-induced enzyme induction. 20 In the dogs of this report, no histologic evidence of cholestasis was found. Therefore, the ALP elevations likely were attributable to phenobarbital-induced enzyme changes. 12 In dogs treated with glucocorticoids, the ALP can remain elevated for weeks to months despite discontinuation of the drug. 20,21 ALP increases had declined to within the reference range after 3 weeks, and had resolved within 5 weeks in the dogs reported here. Phenobarbital-induced ALP changes possibly resolved quickly because phenobarbital levels would rapidly decline after discontinuation (along with its enzymeinducing properties), whereas effects of glucocorticoids persist after the drug has been eliminated. 21 Serum ALT is increased secondary to hepatocellular damage or drug-induced enzyme induction. 22 Serum AST is often concurrently elevated when hepatocellular injury is present. 22 In the dogs of this study, neither cytologic evidence of hepatocellular damage nor AST elevation occurred, supporting the idea that the ALT elevation was induced secondary to phenobarbital. 12 The half-life of serum ALT is approximately 1-2 days, and ALT is expected to decrease over 1-2 weeks after hepatic damage ceases. 22 In a study of 6 dogs with hepatopathy induced by glucocorticoid administration, ALT elevations persisted for 6 weeks after discontinuation of the steroids. 21 This is comparable to the 5 weeks that it took for the dogs of this report to return to pretreatment values. Although reasons for this persistent elevation are unknown, it should be noted that none of the ALT values were above reference ranges after discontinuation of phenobarbital.

GGT can be elevated secondary to drug-induced hepatic enzyme induction or cholestasis. 20, 22 GGT is more specific but a less sensitive indicator of liver disease than is ALP. 23 The dogs of this report had no significant changes in GGT at 27 weeks of phenobarbital administration, although significant increases were reported at weeks 13-21. 12 This supports the theory that GGT is less influenced by enzymeinducing drugs than is ALP. Although reasons for a significant increase in GGT after discontinuation of phenobarbital are unknown, it should be noted that none of the GGT values were above reference ranges during that time.

Previous studies demonstrated a decrease in serum albumin after long-term phenobarbital administration in dogs. 8 Although the dogs in this report did not have significantly decreased serum albumin after 27 weeks of drug administration, a significant increase occurred at weeks 2, 5, 7, and 9 after discontinuation of phenobarbital. This finding could support the idea that phenobarbital induces a defect in albumin synthesis, with a rebound effect resulting in an increase in albumin after the drug is discontinued. Also, this increase in albumin could represent subclinical dehydration because the dogs' water consumption possibly decreased after discontinuation of the drug.

Detection of hypothyroidism in dogs receiving phenobarbital can be difficult, because signs such as weight gain and lethargy are common findings in both hypothyroid dogs and in dogs receiving phenobarbital. 1, 3, 24 In addition, hypercholesterolemia is common in hypothyroidism and has been reported after phenobarbital administration. 12, 24 The mechanism of T 4 decreases in dogs receiving phenobarbital remains unproven. Phenobarbital-induced hepatic enzyme induction may result in increased clearance of triiodothyronine (T 3 ) and T 4 by the liver, as is the case in rodents. 13 Increased conversion of T 4 to T 3 in peripheral tissues may also play a role. 10, 11 Subsequent to decreased peripheral T 4 concentrations, TSH concentration may be increased as a result of loss of feedback. 24 In the dogs of this report, thyroid hormone changes resolved in 1 (TT 4 ) to 5 (FT 4 ) weeks after phenobarbital was discontinued. Mild elevations in TSH concentrations that occurred during phenobarbital administration resolved immediately after discontinuation of the drug at week 27. 12 A lack of TSH increase upon phenobarbital withdrawal supports the theory that hypothalamic-pituitary-thyroid gland axis suppression plays a minimal role in TT 4 and FT 4 depression during phenobarbital administration. Therefore, other mechanisms such as increased metabolism of thyroid hormone by the liver may be more likely. Perhaps if TSH concentrations are increased during the withdrawal period, a diagnosis of primary hypothyroidism should be considered. However, careful and repeated evaluation of the patient's thyroid status is recommended to confirm a diagnosis of hypothyroidism because FT 4 concentrations could still be depressed by 10 weeks after withdrawal (see Fig 3) . Further studies that follow dogs for a longer time period are needed to determine exactly how long thyroid hormone changes persist after phenobarbital is withdrawn. Further studies might also evaluate the measurement of TT 4 and FT 4 6 hours post-TSH injection in normal dogs before, during, and after chronic phenobarbital therapy for its usefulness in accurately measuring thyroid function in dogs during phenobarbital therapy. Based on the findings of this study, it is recommended that thyroid values be evaluated at least 6 weeks after cessation of phenobarbital.

In summary, the findings of our study support the idea that changes in liver enzymes, albumin, cholesterol, and thyroid parameters induced by phenobarbital in normal dogs treated for 27 weeks resolve 1-5 weeks after cessation of therapy. These data may be of aid to practitioners in the evaluation of dogs with suspected hepatotoxicosis secondary to phenobarbital administration, of dogs on phenobarbital suspected of having hypothyroidism, and in the general screening of dogs from which phenobarbital has been withdrawn. 

Goodman and Gilman's the Pharmacologic Basis of Therapeutics

Management of canine epilepsy with phenobarbital and potassium bromide

Anticonvulsant drugs and analeptic agents

Neutropenia and thrombocytopenia in three dogs treated with anticonvulsants

Hepatic cirrhosis associated with long-term anticonvulsant therapy in dogs

Compromised hepatic function in dogs treated with anticonvulsant drugs

Effects of phenobarbital administration on results of serum biochemical analyses and adrenocortical function tests in epileptic dogs

Hypothyroid diseases

Textbook of Veterinary Internal Medicine

Effects of drugs on endocrine tests

Effects of Long Term Phenobarbital Treatment on the Liver, Thyroid, and Adrenal Axis in Dogs

The effect of phenobarbital on the metabolism and excretion of thyroxine in rats

The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland

Analysis of repeated measures

Drug-induced hepatic disease of dogs and cats

Hepatotoxicity of phenobarbital in dogs: 18 cases (1985-1989)

Diseases of the liver

Liver function

Sequential morphologic and clinicopathologic alterations in dogs with experimentally induced glucocorticoid hepatopathy

Gastrointestinal, pancreatic, and hepatic disorders

Diagnostic efficacy of serum alkaline phosphatase and ␥-glutamyltransferase in dogs with histologically confirmed hepatobiliary disease

Canine and Feline Endocrinology and Reproduction

This study was completed at Louisiana State University School of Veterinary Medicine, Baton Rouge, LA. Support was provided by the Departments of Veterinary Clinical Sciences and Veterinary Physiology, Pharmacology, and Toxicology, School of Veterinary Medicine, Louisiana State University. We thank Gaye Gomila for her technical support.